Profit growth for Dr Martens
Dr Martens has reported a 61.3% increase in adjusted profit before tax for the 52 weeks ended March 29, 2026, as the company continued its shift towards a consumer-first operating model.
Adjusted PBT reached £55 million (€64.4 million), compared to £34.1 million (€39.9 million) a year earlier, while revenue declined 2.9% to £764.9 million (€895.3 million). Adjusted EBIT rose 30.6% to £79.3 million (€92.8 million).
Chief executive officer Ije Nwokorie said the business had returned to profit growth while improving revenue quality, margins and cash generation.
The company said footwear categories including the Lowell, Buzz and Zebzag product families performed strongly during the year, while shoe revenues increased 19%. Wholesale growth in EMEA rose 7.6% at constant currency, supported by healthy order books.
Dr Martens said gross margin improved by 120 basis points to 66.2%, while non-marketing operating costs fell 6%.
Looking ahead, the company said FY27 would mark the start of the “scale” phase of its strategy, with increased investment planned for brand marketing and retail store upgrades.
